|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.00 GBX | -1.39% |
|
+5.19% | +22.41% |
| 24/02 | Avacta hails new data supporting proprietary preCision platform | AN |
| 24/02 | Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | GBX 0.8 | +12.68% | 4 | ||||||
| €841.08 | +37.03% | 15 | ||||||
| CN¥133.13 | +46.5% | 18 | ||||||
| $212.53 | +52.35% | 19 | ||||||
| $113.23 | +42.05% | 18 | ||||||
| HK$39.71 | +30.59% | 24 | ||||||
| DKK 2,229.78 | +30.97% | 14 | ||||||
| HK$153.88 | +58.36% | 21 | ||||||
| $23.49 | +94.72% | 13 | ||||||
| HK$536.92 | +36% | 17 | ||||||
| $46.83 | +13.56% | 18 | ||||||
| $667.57 | +50.07% | 14 | ||||||
| - | - | ₩7,70,000 | +44.74% | 1 | ||||
| $109 | +99.71% | 9 | ||||||
| HK$86.69 | +11.24% | 15 | ||||||
| $14.8 | +76.4% | 5 | ||||||
| NT$757 | +15.22% | 7 | ||||||
| $143.94 | +46.98% | 17 | ||||||
| $81.36 | +47.8% | 11 | ||||||
| $91.61 | +52.53% | 18 | ||||||
| Average | 38,814.17 | +44.98% | 14 | ||||||
| Weighted average by Cap. | 23,760.93 | +45.24% | 16 |
- Stock Market
- Equities
- AVCT Stock
- Sector Avacta Group Plc
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition